Even though our criteria for significance were not met, there was a trend towards a higher frequency of IL17-expressing CD3+CD8− T-cells and CD3+CD8+ T-cells in natalizumab-treated MS patients (Figure 5). Here, IL17A is linked to myeloid sarcoma.